findmyKOL

Ana Aparicio, MD

Enriched profile

Professor, Genitourinary Medical Oncology, Division of Cancer Medicine · The University of Texas MD Anderson Cancer Center

ORCID↗NPI↗
✓ Full profile
Region🇺🇸 Houston, TX · South Central · United StatesSpecialtyHematology / OncologyFocusProstate Cancer Treatment and Research+4
Active KOLEmergingfindmyKOL type: EliteLatest publication2026Online presenceverified 2026Payments2021–2025NIH funding2023–2026

Ana Aparicio is Professor, Genitourinary Medical Oncology, Division of Cancer Medicine at The University of Texas MD Anderson Cancer Center. OpenAlex indexes 562 publications with 13,888 citations (h-index 54); ClinicalTrials.gov lists 10 registered studies with this person as an investigator.

Data verified 7 Sept 2026

Overview

Updated 14 Oct 2026

Ana Aparicio is Professor, Genitourinary Medical Oncology, Division of Cancer Medicine at The University of Texas MD Anderson Cancer Center. The public record shows 562 publications with 13,888 citations (h-index 54), centered on Prostate Cancer Treatment and Research, Cancer Genomics and Diagnostics, Prostate Cancer Diagnosis and Treatment. It also documents an investigator role on 10 registered clinical trials, industry payments reported by 24 companies, 1 NIH-funded awards (2023–2026).

  • Most recent indexed publication: 2026 · Prostate cancer and prostatic diseases
  • Top research focus: Prostate Cancer Treatment and Research
  • 10 registered trials on ClinicalTrials.gov
  • Open Payments reporting from 24 companies

Generated from the cited public record · current as of 14 Oct 2026. Every fact links its source below.

Indications focus

from trials led + research topics
Prostate Cancer8 trialsKidney Cancer / RCC2 trialsCarcinoma, Neuroendocrine2 trialsBladder / Urothelial Cancer1 trialCarcinoma, Small Cell1 trialMelanoma1 trialUveal Melanoma1 trial

Research focus

OpenAlex concept fingerprint
Prostate Cancer Treatment and ResearchCancer Genomics and DiagnosticsProstate Cancer Diagnosis and TreatmentCancer, Lipids, and MetabolismRadiopharmaceutical Chemistry and Applications

Drugs & molecules

across trials, industry payments and publications
Xtandigeneric · EnzalutamideClinical trials—Industry payments18Publications2Jevtanageneric · CabazitaxelClinical trials—Industry payments3Publications1Cabometyxgeneric · CabozantinibClinical trials—Industry payments21Publications—Erleadageneric · ApalutamideClinical trials—Industry payments9Publications—Talzennageneric · TalazoparibClinical trials—Industry payments8Publications—Orgovyxgeneric · RelugolixClinical trials—Industry payments7Publications—Opdivogeneric · NivolumabClinical trials—Industry payments4Publications—Provengegeneric · Sipuleucel-TClinical trials—Industry payments4Publications—Kyprolisgeneric · CarfilzomibClinical trials—Industry payments2Publications—Pluvictogeneric · Vipivotide tetraxetanClinical trials—Industry payments2Publications—Akeegageneric · Abiraterone / niraparibClinical trials—Industry payments1Publications—Balversageneric · ErdafitinibClinical trials—Industry payments1Publications—

Works with

trial sponsors and companies reporting payments
Exelixis Inc.Clinical trials—Industry payments21Pfizer Inc.Clinical trials—Industry payments15Abbvie Inc.Clinical trials—Industry payments11Janssen Research & Development, LLCClinical trials—Industry payments10E.R. Squibb & Sons, L.L.C.Clinical trials—Industry payments9Astellas Pharma US IncClinical trials—Industry payments8M.D. Anderson Cancer CenterClinical trials8Industry payments—Merck Sharp & Dohme LLCClinical trials—Industry payments8Daiichi Sankyo Inc.Clinical trials—Industry payments6GlaxoSmithKline, LLC.Clinical trials—Industry payments5Janssen Biotech, Inc.Clinical trials—Industry payments5Dendreon Pharmaceuticals LLCClinical trials—Industry payments4Janssen Scientific Affairs, LLCClinical trials—Industry payments4Amgen Inc.Clinical trials—Industry payments2Astellas Pharma Global DevelopmentClinical trials—Industry payments2AstraZeneca Pharmaceuticals LPClinical trials—Industry payments2Genzyme CorporationClinical trials—Industry payments2Macrogenics, Inc.Clinical trials—Industry payments2National Cancer Institute (NCI)Clinical trials2Industry payments—Novartis Pharmaceuticals CorporationClinical trials—Industry payments2Astellas Pharma Europe BVClinical trials—Industry payments1Aveo Pharmaceuticals, Inc.Clinical trials—Industry payments1Bayer Healthcare Pharmaceuticals Inc.Clinical trials—Industry payments1Boehringer Ingelheim RCV GmbH & Co KGClinical trials—Industry payments1Regeneron Healthcare Solutions, Inc.Clinical trials—Industry payments1Sanofi-Aventis U.S. LLCClinical trials—Industry payments1

Scholarship

indexed output and impact (OpenAlex)
View publications ↓
562publications

Distinct works indexed by OpenAlex, matched via ORCID; 25 in PubMed.

13,888citations

Total citations across indexed works.

54h-index

Hirsch index (OpenAlex). i10-index 113.

Clinical & industry

trials, payments and federal funding
10clinical trials

Investigator role on registered studies.

View trials ↓
24companies · 2021–2025

Companies reporting payments to CMS. Facts, not judgments.

View payments ↓
1NIH grants · 2023–2026

Federally funded research awards.

View funding ↓

Contact

The practice address and phone this provider lists in the federal NPPES (CMS) registry.

Practice address

Telephone

Practice address and telephone from the federal NPPES registry.

Sign in to view contact details →

Clinical trials

Updated 14 Oct 2026

Listed as an investigator on 10 registered studies on ClinicalTrials.gov. The most recent:

All 10 trial records: search, sort and filter.Explore →

Industry payments

Updated 14 Oct 2026

24 companies reported payments to CMS in program years 2021–2025. These are public disclosures, not judgments. The latest:

All 45 payment records: search, sort and filter.Explore →
View the CMS Open Payments record ↗

Medicare prescribing footprint (2024)

The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.

  • Cancer & immunology

    42.7%
    Androgen Receptor Inhibitor42.7%
    Xtandi100%
    Part D<11 patients

  • Metabolism & gastrointestinal

    40%
    Corticosteroid40%
    Prednisone100%
    Part D≥13 patients

  • Respiratory

    17.3%
    Opioid Agonist17.3%
    Hydrocodone-Acetaminophen100%
    Part D<11 patients
Where care is delivered (Part B)100% facility · 0% office

Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.

NIH funding

Updated 14 Oct 2026

1 NIH research award on record, funded 2023–2026 per NIH RePORTER. The latest:

All 5 award records: search, sort and filter.Explore →

Congress activity

Updated 14 Oct 2026

84 congress contributions (2004–2025) across AACR, ASCO, ASTRO, ESMO per OpenAlex. The most recent:

All 84 congress records: search, sort and filter.Explore →

Published abstracts are attributed via the same ORCID-disambiguated authorship as publications, so each is DOI-verified. Podium roles (invited talks, session chairs) and oral/poster type are added as program data is confirmed.

Publications

Updated 14 Oct 2026

Their five most recent publications, matched to their ORCID record and linked to PubMed.

All 25 publications: search, sort and filter.Explore →

Most-cited works

by citation count (OpenAlex)
  1. 01
    Epigenetics in human disease and prospects for epigenetic therapy
    Article3,232 citations2004
    doi.org ↗
  2. 02
    Primary results from IMpassion131, a double-blind, placebo-controlled, randomised phase III trial of first-line paclitaxel with or without atezolizumab for unresectable locally advanced/metastatic triple-negative breast cancer
    Article738 citations2021
    doi.org ↗
  3. 03
    Neoplastic meningitis
    Article489 citations2002
    doi.org ↗
  4. 04
    Platinum-Based Chemotherapy for Variant Castrate-Resistant Prostate Cancer
    Article474 citations2013
    doi.org ↗
  5. 05
    Aggressive Variants of Castration-Resistant Prostate Cancer
    Article431 citations2014
    doi.org ↗
All 562 cited works: search, sort and filter.Explore →

Network

Updated 14 Oct 2026

The people this person publishes with most, by number of co-authored papers. Names link to their own profile when we have one.

Christopher J. Logothetis349Patricia Troncoso285Paul G. Corn280Amado J. Zurita173Nora M. Navone128Sumit K. Subudhi119Nicholas E. Navin112Eleni Efstathiou112John C. Araujo110Emi Sei107Naveen Ramesh107Shanshan Bai102Yuehui Zhao101Ping Xu97Min Hu97Louis L. Pisters82Bradley M. Broom75Peter D.A. Shepherd73Elba S. Vázquez71Estefanía Labanca70Jianhua Zhang69Arul M. Chinnaiyan56Xinhai Wan56Patrick G. Pilié53Sankar N. Maity53Rebecca S. Tidwell50Andrew W. Hahn49Padmanee Sharma48Miao Zhang47Nallasivam Palanisamy44Vikas Kundra44Scott A. Tomlins43Ganiraju C. Manyam43Rama Soundararajan43Elsa M. Li-Ning-Tapia42Brian F. Chapin42John W. Davis42Murali K. Ravoori42Lakshmi P. Kunju42Shannon L. Carskadon41

Online presence

Updated 14 Oct 2026

This person's own public accounts first, then places where others mention them. Two different things, listed separately.

Owned accounts

public accounts run by this person
  • Doximity

    doximity.com/pub/ana-aparicio-md

    verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →doximity.com ↗

Mentions by others

where others cite or feature them
  • Other

    pcf.org/our-work/scientific-leadership/scientific-advisory-board/ana-aparicio-md

    verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →pcf.org ↗
  • Other

    urotoday.com/video-lectures/advanced-prostate-cancer/video/5239-clinical-and-molecular-criteria-for-aggressive-variant-prostate-cancer-ana-aparicio.html

    provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →urotoday.com ↗
  • X / Twitter

    X (Twitter): @aapariciomd

    provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →x.com ↗
  • LinkedIn

    LinkedIn: Ana Aparicio - Professor - MD Anderson Cancer Center

    provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →linkedin.com ↗
  • X / Twitter

    X/Twitter: @aapariciomd

    provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →x.com ↗
  • X / Twitter

    X/Twitter handle @aapariciomd (identity not independently fetch-verified; found via search, page not opened)

    provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →x.com ↗
  • X / Twitter

    X/Twitter handle @aapariciomd (Ana Aparicio, MD)

    provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →x.com ↗

We list an account only when the public record ties it to this person. verified means we've confirmed the match in more than one place; provisional means it looks right but we're still confirming.

Background & recognition

Updated 14 Oct 2026

Credentials, appointments and honors, newest first, each linked to the public source it came from.

Education

degrees and training on record
  • Board Certification

    Medical Oncology

    2023
    verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →faculty.mdanderson.org ↗
  • Board Certified

    Medical Oncology

    2023
    verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →faculty.mdanderson.org ↗
  • Board Certified

    Medical Oncology

    2023
    provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →faculty.mdanderson.org ↗
  • Board Certification

    Hematology

    2003
    verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →faculty.mdanderson.org ↗
  • Board Certified

    Medical Oncology

    2003
    verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →faculty.mdanderson.org ↗
  • Medical Oncology & Hematology Fellowship

    USC/Norris Cancer Center

    2003
    verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →faculty.mdanderson.org ↗
  • Clinical Fellowship

    Medical Oncology and Hematology, USC/Norris Comprehensive Cancer Center

    2003
    verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →faculty.mdanderson.org ↗
  • Board Certification

    Internal Medicine

    2000
    verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →faculty.mdanderson.org ↗
  • Internal Medicine Residency

    UCLA/West LA VA Medical Center

    2000
    verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →faculty.mdanderson.org ↗
  • Board Certified

    Internal Medicine

    1998
    verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →faculty.mdanderson.org ↗
  • MD

    Universidad Autónoma de Madrid, Spain

    1995
    verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →faculty.mdanderson.org ↗

Editorial & leadership roles

journal and society appointments
  • Member

    Novartis/ESMO-affiliated Commercial Advisory Board

    2027
    provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →faculty.mdanderson.org ↗
  • Medical Director

    Faculty Research Support-Clinical Research

    2023
    verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →faculty.mdanderson.org ↗
  • Medical Director

    Faculty Research Support-Clinical Research, MD Anderson Cancer Center

    2023
    verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →faculty.mdanderson.org ↗
  • Editorial Review Board Member

    Prostate Cancer and Prostatic Diseases

    2022
    verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →faculty.mdanderson.org ↗
  • Member

    NCI Genitourinary Steering Committee Prostate Cancer Task Force

    2022
    verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →faculty.mdanderson.org ↗
  • Member

    NCI Genitourinary Steering Committee

    2022
    verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →faculty.mdanderson.org ↗
  • Editorial Review Board

    Prostate Cancer and Prostatic Diseases

    2022
    verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →faculty.mdanderson.org ↗
  • Director

    Clinical Research Group, Genitourinary Medical Oncology

    2020
    verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →faculty.mdanderson.org ↗
  • Director of Clinical Research Group

    Genitourinary Medical Oncology, MD Anderson Cancer Center

    2020
    verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →faculty.mdanderson.org ↗
  • Editorial Review Board Member

    American Cancer Society

    2013
    verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →faculty.mdanderson.org ↗
  • Chair

    Advisory Council of Clinical Research Leaders, MD Anderson Cancer Center

    verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →faculty.mdanderson.org ↗
  • Member

    Scientific Advisory Board, Prostate Cancer Foundation

    verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →pcf.org ↗
  • Member

    Scientific Advisory Board & Awards Committee, Prostate Cancer Foundation

    verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →pcf.org ↗
  • Member

    NCI Genitourinary Steering Committee Prostate Cancer Task Force

    verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →faculty.mdanderson.org ↗
  • Chair

    Advisory Council of Clinical Research Leaders, MD Anderson

    verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →faculty.mdanderson.org ↗
  • Chair

    Advisory Council of Clinical Research Leaders, MD Anderson (Present)

    verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →faculty.mdanderson.org ↗

Awards & honors

honors on the public record

Secondary affiliations

appointments beyond the home institution
  • Medical Director

    Faculty Research Support-Clinical Research, MD Anderson Cancer Center

    2023
    verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →faculty.mdanderson.org ↗
  • Director

    Clinical Research Group, Genitourinary Medical Oncology, MD Anderson Cancer Center

    2020
    verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →faculty.mdanderson.org ↗
  • Associate Member

    UT Graduate School of Biomedical Sciences

    2017
    verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →faculty.mdanderson.org ↗
  • Associate Member

    The University of Texas Graduate School of Biomedical Sciences at Houston

    2017
    verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →faculty.mdanderson.org ↗

Media & interviews

press, podcasts and appearances

Every item links to where we found it. verified means we've confirmed it in more than one place; provisional means we found it and are still confirming.

Similar KOLs

Other experts from the same institution or the same specialty.